Inhibitor Therapeutics, Inc.
INTI · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 1.03 | 0.03 | -0.00 | 3.52 |
| FCF Yield | -31.23% | -19.40% | 32.39% | -0.39% |
| EV / EBITDA | 14.92 | 13.41 | -333,945.84 | -174.27 |
| Quality | ||||
| ROIC | -73.36% | -41.10% | -5.59% | 83.37% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.97 | 0.89 | 0.97 | 0.74 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | -19.73% | -123.00% | 5,426.15% | 73.29% |
| Safety | ||||
| Net Debt / EBITDA | -17.63 | -23.33 | 155,948.97 | -0.62 |
| Interest Coverage | 0.00 | 0.00 | -28.32 | -21.90 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |